SEC Form 4 · accession 0001451612-26-000016

Kymera Therapeutics, Inc. · KYMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Bruce Booth

Director

Period of report

Jun 23, 2026

Accepted (ET)

Jun 25, 2026 · 9:56 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001815442

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3	Jun 25, 2026	S	37,179	$119.71	D	3,075,906	I	See footnote
Common Stock^F4,F3	Jun 25, 2026	S	112,299	$120.66	D	2,963,607	I	See footnote
Common Stock^F5,F3	Jun 25, 2026	S	40,774	$121.38	D	2,922,833	I	See footnote
Common Stock^F6,F3	Jun 25, 2026	S	4,977	$122.67	D	2,917,856	I	See footnote
Common Stock^F7,F3	Jun 25, 2026	S	10,860	$123.62	D	2,906,996	I	See footnote
Common Stock^F8,F3	Jun 25, 2026	S	11,711	$124.61	D	2,895,285	I	See footnote
Common Stock^F9,F3	Jun 25, 2026	S	3,716	$125.82	D	2,891,569	I	See footnote
Common Stock^F10,F3	Jun 25, 2026	S	1,609	$126.71	D	2,889,960	I	See footnote
Common Stock^F11,F3	Jun 25, 2026	S	25,075	$127.37	D	2,864,885	I	See footnote
Common Stock^F12,F3	Jun 25, 2026	S	2,197	$128.69	D	2,862,688	I	See footnote
Common Stock^F13,F3	Jun 25, 2026	S	337	$129.61	D	2,862,351	I	See footnote
Common Stock^F2,F14	Jun 25, 2026	S	5,144	$119.71	D	559,524	I	See footnote
Common Stock^F4,F14	Jun 25, 2026	S	15,660	$120.66	D	543,864	I	See footnote
Common Stock^F5,F14	Jun 25, 2026	S	5,689	$121.38	D	538,175	I	See footnote
Common Stock^F6,F14	Jun 25, 2026	S	698	$122.67	D	537,477	I	See footnote
Common Stock^F7,F14	Jun 25, 2026	S	1,517	$123.62	D	535,960	I	See footnote
Common Stock^F8,F14	Jun 25, 2026	S	1,639	$124.61	D	534,321	I	See footnote
Common Stock^F9,F14	Jun 25, 2026	S	522	$125.82	D	533,799	I	See footnote
Common Stock^F10,F14	Jun 25, 2026	S	223	$126.71	D	533,576	I	See footnote
Common Stock^F11,F14	Jun 25, 2026	S	3,507	$127.37	D	530,069	I	See footnote
Common Stock^F12,F14	Jun 25, 2026	S	305	$128.69	D	529,764	I	See footnote
Common Stock^F13,F14	Jun 25, 2026	S	46	$129.61	D	529,718	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.13 to $127.0511 inclusive.
F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.30 to $128.2975 inclusive.
F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.3008 to $129.2819 inclusive.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.3041 to $130.05 inclusive.
F14The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.08 to $120.0798 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (13).
F3These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.08 to $121.0794 inclusive.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.08 to $122.0731 inclusive.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.0858 to $123.08 inclusive.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.09 to $124.08 inclusive.
F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.09 to $125.0292 inclusive.
F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.1194 to $126.115 inclusive.

Remarks

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the second of two filings.